6-溴咪唑并[1,2-a]吡啶-3-甲醛 | 30384-96-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 6-溴咪唑并[1,2-a]吡啶-3-甲醛
• 中文别名: 6-溴咪唑并[1,2-A]吡啶-3-甲醛
• 英文名称: 6-bromoimidazo[1,2-a]pyridine-3-carbaldehyde
• CAS: 30384-96-4
• 化学式: C₈H₅BrN₂O
• mdl: MFCD09864909
• 分子量: 225.044
• InChiKey: LBCRSOFJVLOCIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  温度：2-8°C，保持在惰性气体氛围中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromoimidazo[1,2-a]pyridine-3-carbaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromoimidazo[1,2-a]pyridine-3-carbaldehyde
CAS number: 30384-96-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5BrN2O
Molecular weight: 225.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴咪唑并[1,2-a]吡啶-3-甲醛 在 甲醇 、 sodium tetrahydroborate 、 氯化亚砜 、 水 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 4-((6-bromoimidazo[1,2-a]pyridin-3-yl)methyl)morpholine
  参考文献：
  名称：

  [EN] SUBSTITUTED IMIDAZOPYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  [FR] IMIDAZOPYRIDINES SUBSTITUÉES, LEUR PRÉPARATION ET LEUR UTILISATION COMME MÉDICAMENTS

  摘要：

  这项申请涉及取代咪唑吡啶类化合物，包括它们的组合物以及它们在治疗需要抑制溴结构域的疾病和病况中的用途。例如，该申请涉及取代咪唑吡啶类化合物及其作为溴结构域抑制剂的用途。本申请还涉及治疗或预防增生性疾病、自身免疫性疾病、炎症性疾病、皮肤疾病以及肿瘤和/或癌症等新生物的用途。

  公开号：

  WO2017066876A1
• 作为产物：
  描述：

  氯乙醛 、 N'-(5-溴-2-吡啶)-N,N-二甲基— 以 水 为溶剂， 反应 10.0h， 以86.7%的产率得到6-溴咪唑并[1,2-a]吡啶-3-甲醛
  参考文献：
  名称：

  一种6-溴咪唑并[1.2-a]吡啶-3-甲醛的制备方法

  摘要：

  一种6‑溴咪唑并[1.2‑a]吡啶‑3‑甲醛的制备方法，包括如下步骤：步骤一：2‑氨基‑5‑溴吡啶与N,N‑二甲基甲酰胺二甲基缩醛加入反应器中反应，搅拌反得N,N‑二甲基‑N'‑2‑(5‑溴‑吡啶)基‑甲脒中间体；步骤二：将步骤一所得的N,N‑二甲基‑N'‑2‑(5‑溴‑吡啶)基‑甲脒中间体加入溶剂中，再加入氯乙醛反应，得固体混合物；步骤三：将固体混合物溶于乙酸乙酯，用水和饱和食盐水洗涤，用无水硫酸钠干燥，过滤，除去乙酸乙酯，得6‑溴咪唑并[1.2‑a]吡啶‑3‑甲醛粗品；步骤四：将6‑溴咪唑并[1.2‑a]吡啶‑3‑甲醛粗品重结晶，过滤，得6‑溴咪唑并[1.2‑a]吡啶‑3‑甲醛纯品。本发明的制备方法中反应原料比较易得，价格合理，反应条件温和，易于操作，后处理简单，且产品质量稳定，纯度高。

  公开号：

  CN112225736B

文献信息

• [EN] 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIDINE 2,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE TGF-BÊTA ET PROCÉDÉS D'UTILISATION
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2015157093A1

  公开（公告）日：2015-10-15

  The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

  本发明涉及的化合物包括公式（IV）的化合物，以及一种治疗癌症的方法，包括向患有癌症的受试者施用其中一种化合物，结合另一种癌症治疗方法。这些化合物（IV）抑制TGF-β超家族成员如Nodal或Activin的信号传导。
• [EN] NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES PYRAZOLO CONDENSES
  申请人：LILLY CO ELI

  公开号：WO2004050659A1

  公开（公告）日：2004-06-17

  The current invention relates to compounds of the formula:(Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.

  目前的发明涉及以下式(Ia)的化合物及其药用盐，以及它们作为TGF-beta信号传导抑制剂用于治疗患有癌症和其他疾病的患者的用途，通过给予这些化合物进行治疗。
• [EN] ORAL COMPLEMENT FACTOR D INHIBITORS<br/>[FR] INHIBITEURS ORAUX DU FACTEUR D DU COMPLÉMENT
  申请人：BIOCRYST PHARM INC

  公开号：WO2021072198A1

  公开（公告）日：2021-04-15

  Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

  揭示了式(I)的化合物及其药学上可接受的盐，这些化合物是裂解系统的抑制剂。还提供了包含这种化合物的药物组合物，以及使用这些化合物和组合物治疗或预防由异常裂解系统活性特征的疾病或状况的方法。
• [EN] COMPOUNDS AND THEIR USE AS INHIBITORS OF N-MYRISTOYL TRANSFERASE<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA N-MYRISTOYL TRANSFÉRASE
  申请人：IMP INNOVATIONS LTD

  公开号：WO2017001812A1

  公开（公告）日：2017-01-05

  This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).

  这项发明提供了式（I）的化合物及其盐，具有作为N-肉豆蔻酰转移酶（NMT）抑制剂的活性。该发明还涉及将这类化合物用作药物的用途，特别是在治疗需要抑制N-肉豆蔻酰转移酶以产生治疗或预防效果的疾病或紊乱中，包括原虫感染（如疟疾和利什曼病）、病毒感染（如人类鼻病毒和HIV）以及高增殖性疾病（如B细胞淋巴瘤）。
• Functionalization of the imidazo[1,2-<i>a</i>]pyridine ring in α-phosphonoacrylates and α-phosphonopropionates via microwave-assisted Mizoroki–Heck reaction
  作者：Damian Kusy、Agata Wojciechowska、Joanna Małolepsza、Katarzyna M Błażewska

  DOI：10.3762/bjoc.16.3

  日期：——

  A series of new phosphonocarboxylates containing an imidazo[1,2-a]pyridine ring has been synthesized via the microwave-assisted Mizoroki-Heck reaction. The efficient modification of the imidazo[1,2-a]pyridine ring has been achieved as late-stage functionalization, enabling and accelerating the generation of a library of compounds from a common precursor.

  通过微波辅助的Mizoroki-Heck反应合成了一系列含有咪唑并[1,2-a]吡啶环的新膦酰基羧酸酯。咪唑并[1,2-a]吡啶环的有效修饰已作为后期功能化而实现，从而能够并加速从常见前体生成化合物库。